

November 5, 2022

BSE Limited Department of Corporate Services Floor 25, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001 Scrip Code No: 542665	National Stock Exchange of India Limited Listing Department, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051 Company Symbol: NEOGEN
--	---

Dear Sir/Madam,

Sub: Disclosure under regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015 (“Listing Regulations”)

Ref.: SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019


Pursuant to Regulation 32 of Listing Regulations, we enclose herewith Statement of Deviation / Variation (“Statement”) for the quarter ended September 30, 2022, duly reviewed by the Audit Committee at its meeting held on November 5, 2022.

We hereby confirm that there has been no deviation or variation in the use of proceeds of funds raised through issue of Equity Shares on preferential basis.

This intimation is also being uploaded on the Company’s website at <https://neogenchem.com/announcements/>.

Kindly take the above on your record and disseminate the same for the information of investors.

Thanking you,
Yours faithfully,
For Neogen Chemicals Limited



Unnati Kanani
Company Secretary & Compliance Officer
Membership No: ACS 35131
Place: Thane

Encl: A/a



NEOGEN
CHEMICALS LTD.

Quarterly Reporting for Preferential Issue of Equity Shares under Regulation 32 of Listing Regulation.

Statement of Deviation / Variation in utilisation of funds raised

Name of listed entity	Neogen Chemicals Limited
Mode of Fund Raising	Preferential Issue of Equity Shares
Date of Raising Funds	06-01-2022
Amount Raised (Rs. In crores)	225 crores
Report filed for Quarter ended	30-09-2022
Monitoring Agency	Not applicable
Monitoring Agency Name, if applicable	Not Applicable
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not Applicable
If Yes, Date of shareholder Approval	Not Applicable
Explanation for the Deviation / Variation	Not Applicable
Comments of the Audit Committee after review	Nil
Comments of the auditors, if any	Nil
Objects for which funds have been raised and where there has been a deviation, in the following table	See table below

(Amount in Crores)

Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised till 30.09.2022*	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
a) funding the long term growth and expansion of its existing businesses;	Not Applicable	225	Not Applicable	225	Nil	Nil
b) financing capital expenditure & working capital requirements;						
c) pre-payment and / or repayment of loans;						
d) General corporate purpose; and / or						
e) Any other matters as may be permissible under applicable law(s).						
		225		225		

Deviation or variation could mean:

- (a) Deviation in the objects or purposes for which the funds have been raised or
 (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or
 (c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc.

Name of Signatory	Ketan Vyas
Designation	Chief Financial Officer
Date	05-11-2022

*Funds Utilised includes Rs. 7.3 crore on account of issue related expenses

Registered Office : 1002, Dev Corpora, Cadbury Junction.
 Eastern Express Highway, Thane (W) 400 601, India
CIN No. L24200MH1989PLC050919

E : sales@neogenchem.com
W : www.neogenchem.com

T : +91 22 2549 7300
F : +91 22 2549 7399